New results from NMDP’s groundbreaking ACCESS trial
NMDP shared a post on LinkedIn:
“Big news: Peer-reviewed Journal of Clinical Oncology just published new results from NMDP’s groundbreaking ACCESS trial.
The data show that post-transplant cyclophosphamide (PTCy)—a treatment to prevent GVHD—enables adult patients receiving mismatched unrelated donor (MMUD) transplant to achieve safety and efficacy outcomes comparable to fully matched donor transplant.
This is a major step forward in expanding access to life-saving transplant for all patients. Shoutout to study co-chair, Dr. Al Malki at City of Hope, and our esteemed transplant center physicians leading this initiative and bringing new hope to blood cancer patients! Read more.”
NCODA shared a post by NMDP, adding:
“A powerful reminder of what clinical collaboration can achieve. The ACCESS trial marks real progress in expanding access to life-saving transplants – even for patients without a perfect donor match.Hats off to Dr. Malki, City of Hope, and all researchers involved for pushing the field forward and giving more patients a chance at better outcomes.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023